. Author manuscript; available in PMC: 2019 Jun 17.

Published in final edited form as: J Am Coll Health. 2017 May 8;65(6):380–388. doi: 10.1080/07448481.2017.1312418

Table 3.

Number of adverse event reports following each MenB-4C vaccine dose in the two-dose series by method of report.

	University A		University B
Method of report	Dose 1 n (%)^A	Dose 2 n (%)^B	Dose 1 n (%)^A	Dose 2 n (%)^B
15-minute observation	35 (0.49%)	7(0.11%)	67 (0.68%)	5 (0.06%)
Phone call	53 (0.74%)	36 (0.54%)	126(1.28%)	104(1.35%)
Email	5 (0.07%)	2 (0.03%)	0	0
Clinic visit	63 (0.88%)	51 (0.77%)	115 (1.17%)	78(1.01%)
Pre-dose 2 questionnaire^A	328 (4.95%)	n/a	333 (4.32%)	n/a
Online questionnaire^C	11 (0.15%)	156 (2.35%)	11 (0.11%)	80 (1.04%)
Local hospital surveillance	2 (0.03%)	5 (0.08%)	30 (0.31%)	15(0.19%)
Total	497 (6.96%)	257 (3.88%)	682 (6.94%)	282 (3.66%)

Note.

The percentage is among participants who received dose 1, except for the “pre-dose 2 questionnaire” row, which is among participants who received dose 2.

The percentage is among participants who received dose 2.

The online questionnaire was completed by 51% of participants at University A and 11% at University B.